Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In Brief

This article was originally published in The Gray Sheet

Executive Summary

Spine Wave names CFO: Carmen Diersen signs on as CFO at orthopedic start-up Spine Wave, effective Sept. 1. Diersen will resign from American Medical Systems (AMS) where she helped guide five acquisitions during her CFO tenure, including AMS' $715 mil. purchase of Laserscope in July (1"The Gray Sheet" July 24, 2006, In Brief). Prior to AMS, Diersen spent 12 years in the cardiac rhythm management and spinal surgery businesses at Medtronic. Spine Wave has raised $90 mil. in funding to date, including a Series C financing worth $36.5 mil. this year. The Conn.-based firm plans a full U.S. launch of the StaXx XD expandable vertebral body replacement device this fall. The company is also developing the NuCore injectable nucleus and the StaXx FX fracture repair system. AMS appointed Jill Burchill as interim CFO...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023903

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel